New personalized vaccine aims to fight advanced colon and pancreatic cancers
NCT ID NCT07587827
First seen Jun 01, 2026 · Last updated Jun 19, 2026 · Updated 4 times
Summary
This early-phase trial tests a personalized cancer vaccine called ODI-2001 in 77 people with advanced colon or pancreatic cancer. The vaccine is custom-made for each patient and combined with an immune-boosting drug (ipilimumab). The goal is to find the safest dose and see if it can slow cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHRU Jean Minjoz
Besançon, 25000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Georges-François Leclerc
Dijon, 21000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Personalized cancer vaccine (DNA neoantigen vaccine + MVA viral vector + ipilimumab)
What this could lead to
If successful, this could point toward a new personalized immunotherapy option for advanced colon or pancreatic cancers.
What could go wrong
This is a very early Phase 1 trial with only 77 participants, so it may not show clear benefit. The vaccine includes ipilimumab, which can cause serious immune-related side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.